Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

White House Reassures Drug CEOs: Reimportation Could Be 'Unnecessary'
The Wall Street Journal reports: "Industry representatives met at the White House Tuesday with officials to consider specifics of a cost-saving agreement the industry reached last month with health-care negotiators and to discuss other concerns that the pharmaceutical industry has with the larger health-care overhaul being considered by Congress. As a presidential candidate, President Barack Obama endorsed re-importation, an idea the industry opposes. White House officials have told the industry if the larger health care bill passes, the cost savings will be so great that reimportation will be unnecessary, according to Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America." Some of the pharmaceutical companies represented at the Tuesday meeting included Merck & Co., Pfizer Inc., Amgen Inc., Abbott Laboratories and AstraZeneca.
pharmacy online
GDC Council Meeting - Thursday 11 June 2009
The next meeting of the General Dental Council (GDC) will take place on Thursday 11 June 2009 in the Harvey Goodwin Room, Church House Conference Centre, Dean"s Yard, Westminster, London, SW1P 3NZ from 10:30am.
News of the day
New Horizons An Opportunity To Build A Healthier, Happier Nation, UK
The government launches New Horizons, a major new consultation on how we should care for the mental health of the nation for the next ten years. As the current mental health strategy the National Service Framework draws to a close this autumn, New Horizons is a pivotal opportunity to move on from a model of mental health care based solely on delivering medical services, to a cross-government plan that approaches everyone"s mental wellbeing holistically, and considers the impact of social factors such as unemployment and debt.
Oncology

Cegedim Dendrite Launches Innovative COUNTERxFEIT DETECT Program

Cegedim Dendrite announced the launch of COUNTERxFEIT DETECT, a new offering that will assist pharmaceutical companies in identifying counterfeit product and determining where it entered their United States supply chains. Cegedim Dendrite is the leading provider of compliance technology solutions and services in the pharmaceutical industry. Counterfeit medicines represent a significant public health and safety issue for consumers. It also poses serious business and financial risks for manufacturers, including possible liability issues, lost revenue, erosion of brand confidence and negative public perception. COUNTERxFEIT DETECT is designed for pharmaceutical companies that need to identify and determine the of counterfeit, contaminated or adulterated product. Cegedim Dendrite facilitates this by coordinating the purchase of non-controlled, finished drug products from contract manufacturers or distributors, using an independent pharmaceutical buyer. The product is shipped to a testing facility or the pharmaceutical company"s analytical lab, where the product is analyzed. "Drug counterfeiting is a concern in the pharmaceutical industry with estimates indicating that upward of 8% of pharmaceutical medicines worldwide may be counterfeit," explained Bill Buzzeo, Cegedim Dendrite Vice President and General Manager, Compliance Solutions and OneKey. "As part of their anti-counterfeiting programs, pharmaceutical companies should acquire finished drug products within the supply chain for analysis and testing to ensure their quality. We seamlessly facilitate that process, and as far as we know, we"re the only company that offers this type of program." Cegedim Dendrite"s independent purchasing of finished drug product takes the burden off the pharmaceutical company"s internal res. COUNTERxFEIT DETECT is fully secure and includes appropriate audit trail documentation that provides insight into the full acquisition chain associated with the independent pharmacy"s purchase. "If an independent party is making the purchase," said Buzzeo, "the pharmaceutical company can better show that they had a random sample for testing and that the process was not tainted by anyone internally with false motive." Cegedim Dendrite has been providing comprehensive compliance solutions to a broad range of pharmacy clients for 20 years. The company employs former state and federal regulators whose firsthand experience with compliance, fraud and abuse issues enable them to develop real-world prevention programs. About Cegedim Dendrite Cegedim Dendrite is the life sciences industry"s leading provider of Customer Relationship Management (CRM) solutions. Pharmaceutical by design, the company"s innovative business solutions and global reach incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Dendrite enables more than 200,000 users in many of the world"s top companies to stay ahead of market challenges. Cegedim Dendrite also provides sales, marketing and regulatory compliance solutions in more than 80 countries. Cegedim Dendrite is part of the France-based Cegedim S.A. Group. To learn more, please visit http://www.cegedimdendrite.com. Cegedim


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009